Business
Esperion Announces the Appointment of Alan Fuhrman to its Board of Directors
ANN ARBOR, Mich., March 18, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the appointment of Alan Fuhrman as a Class III director, with a
About this update from Esperion Therapeutics, Inc.
[{"type":"text","content":"ANN ARBOR, Mich., March 18, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the appointment of Alan Fuhrman as a Class III director, with a term expiring at the 2022 meeting of stockholders.\n \"On behalf of the Lipid Management team and our directors, I am very pleased to welcome Alan to the Esperion board. His extensive financial leadership experience will be extremely valuable as Esperion transitions to both developing and commercializing oral, LDL-C lowering medicines,” said Tim Mayleben, president and chief executive officer of Esperion. \"With the recent U.S. approvals of the NEXLETOLTM (bempedoic acid) and NEXLIZETTM (bempedoic acid and ezetimibe) tablets, we are poised to deliver on the commercial promise of our medicines while continuing to advance the development of oral, once-daily LDL-C lowering medicines for the millions of patients in need. Alan’s accounting and financial acumen will help the company to successfully and responsibly navigate these opportunities for our shareholders.” Mr. Fuhrman brings over 20 years of executive financial experience in biotechnology, medical devices, technology and services. He has experience in a wide variety of both public and private company financial transactions. Mr. Fuhrman is a member of the board of directors for SpringWorks Therapeutics and is a member of the board of directors of Checkmate Pharmaceuticals. Alan is currently chief financial officer of Amplyx Pharmaceuticals, a biotechnology company focused on developing novel products for life-threatening infections. He previously served as CFO of Mirna Therapeutics, a clinical-stage microRNA company that merged with Synlogic in August 2017 and at Ambit Biosciences, where he helped lead the company through its initial public offering and oversaw financial, investor and administrative operations until its sale to Daiichi Sankyo in 2014. \"I’m pleased to be joining Esperion at this pivotal time in their evolution,\" said Mr. Fuhrman. “I’m confident in the mission of the Esperion team to deliver lipid management for everybody. There are millions of patients that stand to benefit from the company’s ability to successfully execute on its commercial strategy.” Esperion Therapeutics Through scientific and clinical excellence, and a deep understanding of cholesterol biology, the experienced Lipid Management Team at...